Shimadzu buys CDMO AlsaChim
The deal – financial terms of which were not disclosed – adds AlsaChim’s range of isotope-labelled standards compounds, metabolites and pharmaceutical related substances to Shimadzu portfolio of analytical standards.
Shimadzu cited AlsaChim’s presence in the clinical trial supply and analytical sectors as an important driver for the takeover. The Japanese firm also predicted its analytical testing kits business would benefit from the acquisition.
Bjoern-Thoralf Erxleben, Senior Manager Analytic Shimadzu Europa, said: “With AlsaChim, we have a strong partner in our organization who is able to finalize and validate new application kits and utilize the developments done by EUIC and transfer them into ready-to-use products.”
Shimadzu also predicted that AlasCHim – which will retain its name – will expand its customer-base.
